Login | Register

FDA Approves New Lung Cancer Diagnostic “Cobas EGFR Mutation Test”

The U.S. Food and Drug Administration (FDA) has approved the cobas EGFR Mutation Test, a companion diagnostic for the cancer drug Tarceva (erlotinib). This is the first FDA-approved companion diagnostic that detects epidermal growth factor receptor (EGFR) gene mutations, which are present in approximately 10 percent of non-small cell lung cancers (NSCLC)...

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *